Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy

This publication has 42 references indexed in Scilit:

• Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
  Journal of Clinical Oncology, 2008
• Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
  BMC Cancer, 2008
• Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
  Journal of Clinical Oncology, 2007
• Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
  Journal of Clinical Oncology, 2007
• Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
  Journal of Clinical Oncology, 2007
• Estimates of the cancer incidence and mortality in Europe in 2006
  Annals of Oncology, 2007
• Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer
  Journal of Clinical Oncology, 2006
• Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
  Investigational New Drugs, 2005
• Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate
  Journal of Clinical Oncology, 2004
• Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
  Journal of Clinical Oncology, 2004